Table 1.
Incidence of Selected Comorbidities Among Patients <60 Years Who Underwent the Fontan Procedure and Who Survived 30 Days After Fontan
| Comorbidity | Post‐Fontan, y | ||||
|---|---|---|---|---|---|
| <1 (N=98) | 1–3 (N=92) | 3–5 (N=76) | 5–10 (N=65) | >10 (N=50) | |
| FALD+ | |||||
| CHF | 5 (5.1) | 6 (6.5) | 4 (5.3) | 4 (6.2) | 7 (14.0) |
| AF | 2 (2.0) | 0 | 4 (5.3) | 9 (13.8) | 16 (32.0) |
| Pulmonary hypertension | 1 (1.0) | 0 | 2 (2.6) | 1 (1.5) | 3 (6.0) |
| Heart block | 1 (1.0) | 1 (1.1) | 1 (1.3) | 3 (4.6) | 6 (12.0) |
| Atrial hypertension | 3 (3.1) | 2 (2.2) | 2 (2.6) | 1 (1.5) | 4 (8.0) |
| Acute renal failure | 1 (1.0) | 1 (1.1) | 4 (5.3) | 1 (1.5) | 5 (10.0) |
| Supraventricular tachycardia | 0 | 3 (3.3) | 2 (2.6) | 2 (3.1) | 13 (26.0) |
| Protein‐losing enteropathy | 3 (3.1) | 2 (2.2) | 2 (2.6) | 1 (1.5) | 3 (6.0) |
| Comorbidity | <1 (N=414) | 1–3 (N=372) | 3–5 (N=324) | 5–10 (N=297) | >10 (N=238) |
|---|---|---|---|---|---|
| FALD− | |||||
| CHF | 19 (4.6) | 14 (3.8) | 11 (3.4) | 13 (4.3) | 16 (6.7) |
| AF | 4 (1.0) | 9 (2.4) | 8 (2.5) | 13 (4.3) | 31 (13.0) |
| Pulmonary hypertension | 8 (1.9) | 7 (1.9) | 5 (1.5) | 2 (0.7) | 2 (0.8) |
| Heart block | 5 (1.2) | 6 (1.6) | 4 (1.2) | 4 (1.4) | 7 (2.9) |
| Atrial hypertension | 5 (1.2) | 4 (1.1) | 6 (1.8) | 5 (1.7) | 9 (3.8) |
| Acute renal failure | 4 (1.0) | 4 (1.1) | 4 (1.2) | 8 (2.8) | 6 (2.5) |
| Supraventricular tachycardia | 5 (1.2) | 3 (0.8) | 6 (1.8) | 8 (2.8) | 24 (10.1) |
| Protein‐losing enteropathy | 3 (0.7) | 2 (0.5) | 3 (0.9) | 5 (1.7) | 0 |
Data are given as number (percentage) of each group. AF indicates atrial fibrillation; CHF, congestive heart failure; FALD, Fontan‐associated liver disease; FALD−, patients without FALD; and FALD+, patients with FALD.